Clinical Trial Update: Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial evaluating Vyxeos as re-induction therapy for acute myeloid leukemia in patients with persistent disease after induction; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Vyxeos (CPX-351)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Persistent Disease | Phase 1, Phase 2 | Status: RECRUITING